vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded vTv Therapeutics from “sell” to “hold.” Overall, analysts rate the stock “Moderate Buy,” with a consensus price target of $55.83.
• Analyst opinions are mixed: one rates the stock Strong Buy, six Buy, one Hold and one Sell; price targets include $42 from HC Wainwright and $57 from BTIG.
• vTv reported a quarterly loss of $0.94 per share, narrower than the $1.09 loss analysts expected. The stock opened at $21.03, near its 52-week low of $20.56.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other equities analysts have also issued research reports about the company. HC Wainwright decreased their price target on vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Lifesci Capital raised shares of vTv Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 2nd. BTIG Research reiterated a "buy" rating and set a $57.00 price target on shares of vTv Therapeutics in a report on Wednesday, October 14th. Weiss Ratings cut shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Zacks Research raised shares of vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, vTv Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $55.83.

vTv Therapeutics Stock Performance

NASDAQ:VTVT opened at $21.03 on Friday. The company has a market capitalization of $82.86 million, a P/E ratio of -22.86 and a beta of 0.28. The stock's 50 day moving average price is $29.22 and its 200 day moving average price is $33.23. vTv Therapeutics has a 52 week low of $20.56 and a 52 week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.15. As a group, sell-side analysts forecast that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. boosted its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) by 114.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,360 shares of the biotechnology company's stock after acquiring an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in vTv Therapeutics were worth $161,000 as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc NASDAQ: VTVT is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.